Benzinga | Aug 20, 2020 06:31AM EDT

Co-Diagnostics, Inc. Receives Enhanced US Patent Protection For CoPrimer Technology Used In COVID-19 Test

SALT LAKE CITY, Aug. 20, 2020 /PRNewswire/ --Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that the United States Patent and Trademark Office has granted increased patent protection for the Company's novel CoPrimer(tm) technology used in the Company's COVID-19 test kit and its other molecular diagnostic tests. This new patent further validates the uniqueness of the CoPrimer molecule, and provides even more comprehensive protection for all of its potential applications.